Last reviewed · How we verify
Bryostatin for Injection
Activates protein kinase C (PKC)
Activates protein kinase C (PKC) Used for T-cell lymphoma.
At a glance
| Generic name | Bryostatin for Injection |
|---|---|
| Also known as | Bryostatin 1, Bryostatin, NSC 339555, CAS No. 83314-01-6 |
| Sponsor | Blanchette Rockefeller Neurosciences Insitute |
| Drug class | Cytotoxic agent |
| Target | Protein kinase C (PKC) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Bryostatin is a natural product that activates protein kinase C (PKC), a family of enzymes involved in cell signaling pathways.
Approved indications
- T-cell lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |